Tile-Based Radiation Tops Standard for Resected Brain Metastases
The Phase 3 ROADS trial found cesium-131 tiles cut surgical-site recurrence to 1.3% and raised median survival to 42.5 months.
- On Saturday at the 2026 American Society of Clinical Oncology Annual Meeting, researchers presented Phase 3 ROADS trial data showing GammaTile collagen tiles significantly improve survival and tumor control for brain metastases patients compared to standard radiation therapy.
- Standard postoperative stereotactic radiation therapy often involves delays due to surgical recovery and scheduling hurdles, causing roughly 20% of patients to never receive their planned radiation treatment.
- Patients treated with GammaTile experienced a 1.3% surgical bed recurrence rate compared to 15.4% for the SRT group. Median overall survival reached 42.5 months with the tiles, more than double the 17.6 months observed with standard SRT.
- GammaTile allows patients to complete cranial radiation in a median of 1 day, bypassing the 32-day median wait for SRT. This expedited timeline enables earlier return to systemic cancer therapies, GT Medical Technologies reports.
- Study discussant Dr. David Schiff, a neuro-oncologist at the University of Virginia in Charlottesville, noted the survival benefit is "surprising," suggesting potential patient characteristic imbalances. If findings hold, GammaTile could eventually supplant cavity radiosurgery for larger metastases.
14 Articles
14 Articles
Implanted collagen tiles double survival for brain metastasis patients
A multicenter clinical trial led by researchers at The University of Texas MD Anderson Cancer Center has found that implanting collagen tiles during brain surgery to deliver targeted radiation therapy dramatically improved tumor control, lowered the risk of recurrence and improved overall survival compared to current standard of care for patients with newly diagnosed brain metastases in need of surgical resection.
PR Newswire
ROADS Phase 3 Clinical Trial Data Presented at ASCO26 Show GammaTile® Provides Superior Tumor Control Leading to Patients Living Longer Without Recurrence Compared to Standard of Care in Newly Diagnosed Operable Brain Metastases
/PRNewswire/ -- GT Medical Technologies, a company focused on improving the lives of patients with brain tumors, today announced compelling new clinical data...
Tile-Based Radiation Tops Standard for Resected Brain Metastases
(MedPage Today) -- CHICAGO -- Radioactive tiles implanted immediately after the surgical resection of a newly diagnosed brain metastasis improved local control over standard stereotactic radiotherapy (SRT) given weeks later, findings of a phase...
Tile-Based Radiation Therapy Reduces Recurrence Risk in Brain Metastases,
A groundbreaking advancement in the treatment of brain metastases has emerged from a recent multicenter Phase 3 clinical trial led by The University of Texas MD Anderson Cancer Center. This innovative approach involves implanting cesium-131-loaded collagen tiles directly into the surgical cavity during brain tumor resection. The practice has demonstrated a significant reduction in tumor […]
Coverage Details
Bias Distribution
- 87% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
